BACKGROUND:Previous studies have reported inconsistent findings regarding the association between catestatin and outcomes of acute myocardial infarction(AMI).This study aims to investigate the prognostic value of cate...BACKGROUND:Previous studies have reported inconsistent findings regarding the association between catestatin and outcomes of acute myocardial infarction(AMI).This study aims to investigate the prognostic value of catestatin for long-term outcomes in patients with AMI.METHODS:One hundred and sixty-five patients with AMI were enrolled in this series.The plasma catestatin levels at baseline and clinical data were collected.All patients were followed up for four years to investigate whether there were major adverse cardiovascular events(MACEs),including cardiovascular death,recurrent AMI,rehospitalization for heart failure,and revascularization.RESULTS:There were 24 patients who had MACEs during the follow-up period.The MACEs group had significantly lower plasma catestatin levels(0.74±0.49 ng/m L vs.1.10±0.79 ng/m L,P=0.033)and were older(59.0±11.4 years old vs.53.2±12.8 years old,P=0.036).The rate of MACEs was significantly higher in the elderly group(≥60 years old)than in the young group(<60 years old)(23.8%[15/63]vs.8.8%[9/102],P=0.008).The catestatin level was significantly lower in the MACEs group than that in the non-MACEs group(0.76±0.50 ng/m L vs.1.31±0.77 ng/m L,P=0.012),and catestatin was significantly associated with MACEs(Kaplan Meier,P=0.007)among the elderly group,but not in the young group(Kaplan Meier,P=0.893).In the Cox proportional hazards regression,high catestatin was one of the independent factors for predicting MACEs after adjustment for other risk factors(hazard ratio 0.19,95%confidence interval 0.06–0.62,P=0.006)among elderly patients.CONCLUSIONS:Elderly AMI patients with lower plasma catestatin levels are more likely to develop MACEs.Catestatin may be a novel marker for the long-term prognosis of AMI,especially in elderly patients.展开更多
Background Catestatin, a chromogranin A-derived peptide, is a potent antagonist of nicotine-evoked catecholamine release. We know that catecholamine plays an important role in cardiovascular remodeling induced by hype...Background Catestatin, a chromogranin A-derived peptide, is a potent antagonist of nicotine-evoked catecholamine release. We know that catecholamine plays an important role in cardiovascular remodeling induced by hypertension, therefore we hypothesized that catestatin would affect target-organ structure during hypertension. Methods Twelve spontaneously hypertensive rats （SHRs） were randomized to SHR control group and catestatin group, the normal control group was comprised of six healthy Wistar-Kyoto rats of the same age. Tail-cuff blood pressure and pulse rate were obtained at weeks 1, 4 and 8. At the end of the eight-week period, the heart, abdominal aorta and left kidney were excised and weighed, VG staining was done and the intima-media thickness of vessels and the collagen volume fraction were assessed by an image acquisition and analysis system. The proliferating cell nuclear antigen （PCNA） was observed by immunohistochemistry, and real time reverse transcription-polymerase chain reaction （RT-PCR） was used to detect the mRNA levels of proliferative genes including cyclin A, ki67 and PCNA in the abdominal aorta. Results All the parameters in SHR observed in the present study increased significantly compared to Wistar Kyoto rats （P 〈0.01 ）. With intervention with catestatin, the systolic blood pressure decreased slightly but it was not significantly different from the SHR control, the cardiac mass index and left ventricular mass index both decreased significantly, the collagen volume fraction decreased by nearly 30% in the heart, by 25% in vessels and by 10% in the kidney, and the intima-media thickness and expression of proliferative genes, including cyclin A, ki67 and PCNA, in the abdominal aorta also decreased significantly. Conclusions The present study indicated that catestatin could ameliorate proliferating changes of heart, kidney and vessels during hypertension, especially to the deposition of interstitial collagen. Blood pressure was not the main factor to mediate this effect, which suggested that catestatin could become a novel protective factor for hypertensive target organs.展开更多
目的:儿茶酚抑素(catestatin)是一种新发现的具有抑制儿茶酚胺释放作用的内源性神经肽,该文拟探讨血浆儿茶酚抑素在心力衰竭患者中的变化及可能的病理生理意义。方法:入选45例心力衰竭患者及30例健康对照组,采用酶联免疫分析法测定血浆...目的:儿茶酚抑素(catestatin)是一种新发现的具有抑制儿茶酚胺释放作用的内源性神经肽,该文拟探讨血浆儿茶酚抑素在心力衰竭患者中的变化及可能的病理生理意义。方法:入选45例心力衰竭患者及30例健康对照组,采用酶联免疫分析法测定血浆儿茶酚抑素,高效液相色谱分析法测定血浆去甲肾上腺素浓度。结果:与健康对照组相比,心衰患者血浆儿茶酚抑素(0.88±0.30 vs 0.41±0.14 ng/ml)及去甲肾上腺素(421.9±61.4vs 210.2±55.4 pg/ml)显著升高(P<0.01);治疗后均明显降低(P<0.01),但未降至健康对照组水平;治疗后儿茶酚抑素/去甲肾上腺素的比值较前显著升高(2.39±0.70 vs 1.95±0.64,P<0.01)。不同NYHA分级的心衰患者间及射血分数正常和降低的心衰患者间血浆儿茶酚抑素没有显著性差异。儿茶酚抑素与左室射血分数、超敏C反应蛋白、肌钙蛋白I无明显相关(P>0.05),但与氨基末端前脑钠肽存在正相关(r=0.38,P<0.05)。儿茶酚抑素诊断心力衰竭的ROC曲线下面积为0.94。结论:心力衰竭患者血浆中的儿茶酚抑素升高,与NTproBNP呈正相关,儿茶酚抑素有可能成为心力衰竭新的生化标志物。展开更多
基金supported by the National Natural Science Foundation of China(81400319)。
文摘BACKGROUND:Previous studies have reported inconsistent findings regarding the association between catestatin and outcomes of acute myocardial infarction(AMI).This study aims to investigate the prognostic value of catestatin for long-term outcomes in patients with AMI.METHODS:One hundred and sixty-five patients with AMI were enrolled in this series.The plasma catestatin levels at baseline and clinical data were collected.All patients were followed up for four years to investigate whether there were major adverse cardiovascular events(MACEs),including cardiovascular death,recurrent AMI,rehospitalization for heart failure,and revascularization.RESULTS:There were 24 patients who had MACEs during the follow-up period.The MACEs group had significantly lower plasma catestatin levels(0.74±0.49 ng/m L vs.1.10±0.79 ng/m L,P=0.033)and were older(59.0±11.4 years old vs.53.2±12.8 years old,P=0.036).The rate of MACEs was significantly higher in the elderly group(≥60 years old)than in the young group(<60 years old)(23.8%[15/63]vs.8.8%[9/102],P=0.008).The catestatin level was significantly lower in the MACEs group than that in the non-MACEs group(0.76±0.50 ng/m L vs.1.31±0.77 ng/m L,P=0.012),and catestatin was significantly associated with MACEs(Kaplan Meier,P=0.007)among the elderly group,but not in the young group(Kaplan Meier,P=0.893).In the Cox proportional hazards regression,high catestatin was one of the independent factors for predicting MACEs after adjustment for other risk factors(hazard ratio 0.19,95%confidence interval 0.06–0.62,P=0.006)among elderly patients.CONCLUSIONS:Elderly AMI patients with lower plasma catestatin levels are more likely to develop MACEs.Catestatin may be a novel marker for the long-term prognosis of AMI,especially in elderly patients.
文摘Background Catestatin, a chromogranin A-derived peptide, is a potent antagonist of nicotine-evoked catecholamine release. We know that catecholamine plays an important role in cardiovascular remodeling induced by hypertension, therefore we hypothesized that catestatin would affect target-organ structure during hypertension. Methods Twelve spontaneously hypertensive rats （SHRs） were randomized to SHR control group and catestatin group, the normal control group was comprised of six healthy Wistar-Kyoto rats of the same age. Tail-cuff blood pressure and pulse rate were obtained at weeks 1, 4 and 8. At the end of the eight-week period, the heart, abdominal aorta and left kidney were excised and weighed, VG staining was done and the intima-media thickness of vessels and the collagen volume fraction were assessed by an image acquisition and analysis system. The proliferating cell nuclear antigen （PCNA） was observed by immunohistochemistry, and real time reverse transcription-polymerase chain reaction （RT-PCR） was used to detect the mRNA levels of proliferative genes including cyclin A, ki67 and PCNA in the abdominal aorta. Results All the parameters in SHR observed in the present study increased significantly compared to Wistar Kyoto rats （P 〈0.01 ）. With intervention with catestatin, the systolic blood pressure decreased slightly but it was not significantly different from the SHR control, the cardiac mass index and left ventricular mass index both decreased significantly, the collagen volume fraction decreased by nearly 30% in the heart, by 25% in vessels and by 10% in the kidney, and the intima-media thickness and expression of proliferative genes, including cyclin A, ki67 and PCNA, in the abdominal aorta also decreased significantly. Conclusions The present study indicated that catestatin could ameliorate proliferating changes of heart, kidney and vessels during hypertension, especially to the deposition of interstitial collagen. Blood pressure was not the main factor to mediate this effect, which suggested that catestatin could become a novel protective factor for hypertensive target organs.
文摘目的:儿茶酚抑素(catestatin)是一种新发现的具有抑制儿茶酚胺释放作用的内源性神经肽,该文拟探讨血浆儿茶酚抑素在心力衰竭患者中的变化及可能的病理生理意义。方法:入选45例心力衰竭患者及30例健康对照组,采用酶联免疫分析法测定血浆儿茶酚抑素,高效液相色谱分析法测定血浆去甲肾上腺素浓度。结果:与健康对照组相比,心衰患者血浆儿茶酚抑素(0.88±0.30 vs 0.41±0.14 ng/ml)及去甲肾上腺素(421.9±61.4vs 210.2±55.4 pg/ml)显著升高(P<0.01);治疗后均明显降低(P<0.01),但未降至健康对照组水平;治疗后儿茶酚抑素/去甲肾上腺素的比值较前显著升高(2.39±0.70 vs 1.95±0.64,P<0.01)。不同NYHA分级的心衰患者间及射血分数正常和降低的心衰患者间血浆儿茶酚抑素没有显著性差异。儿茶酚抑素与左室射血分数、超敏C反应蛋白、肌钙蛋白I无明显相关(P>0.05),但与氨基末端前脑钠肽存在正相关(r=0.38,P<0.05)。儿茶酚抑素诊断心力衰竭的ROC曲线下面积为0.94。结论:心力衰竭患者血浆中的儿茶酚抑素升高,与NTproBNP呈正相关,儿茶酚抑素有可能成为心力衰竭新的生化标志物。
